EUVIMEDEUVIMED entdecken
Open Access

FOXK2 amplification promotes breast cancer development and chemoresistance

Yang Yu, Wen-Ming Cao, Feng Cheng, Zhongcheng Shi, Lili Han, Jinling Yi, Edaise M da Silva, Higinio Dopeso, Hui Chen, Jianhua Yang, Xiaosong Wang, Chunchao Zhang und 1 weitere

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Yang Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC, 20010, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Proliferation, Drug Resistance, Neoplasm, Forkhead Transcription Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogene activation through DNA amplification or overexpression is a crucial driver of cancer initiation and progression. The FOXK2 gene, located on chromosome 17q25, encodes a transcription factor with a forkhead DNA-binding domain. Analysis of genomic datasets reveals that FOXK2 is frequently amplified and overexpressed in breast cancer, correlating with poor patient survival. Knockdown of FOXK2 significantly inhibited breast cancer cell proliferation, migration, anchorage-independent growth, and delayed tumor growth in a xenograft mouse model. Additionally, inhibiting FOXK2 sensitized breast cancer cells to chemotherapy. Co-overexpression of FOXK2 and mutant PI3KCA transformed non-tumorigenic MCF-10A cells, suggesting a role for FOXK2 in PI3KCA-driven tumorigenesis. CCNE2, PDK1, and ESR1 were identified as transcriptional targets of FOXK2 in MCF-7 cells. Small-molecule inhibitors of CCNE2/CDK2 (dinaciclib) and PDK1 (dichloroacetate) exhibited synergistic anti-tumor effects with PI3KCA inhibitor (alpelisib) in vitro. Inhibition of FOXK2 by dinaciclib synergistically enhanced the anti-tumor effects of alpelisib in a xenograft mouse model. Collectively, these findings highlight the oncogenic function of FOXK2 and suggest that FOXK2 and its downstream genes represent potential therapeutic targets in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCell ProliferationDrug Resistance, NeoplasmForkhead Transcription FactorsAnimalsFemaleHumansMice3-Phosphoinositide-Dependent Protein KinasesAntineoplastic AgentsCell MovementCyclin-Dependent Kinase 2Estrogen Receptor alphaGene AmplificationGene Expression Regulation, NeoplasticMCF-7 CellsMice, NudePyruvate Dehydrogenase Acetyl-Transferring KinaseThiazolesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Breast cancerFOXK2Gene amplificationOncogeneTranscription factor

Substanzen

3-Phosphoinositide-Dependent Protein KinasesAntineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2ESR1 protein, humanEstrogen Receptor alphaForkhead Transcription Factorsinterleukin binding factorPDPK1 protein, humanPyruvate Dehydrogenase Acetyl-Transferring Kinase

Autor:innen und Institutionen

  • Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC, 20010, USA.
  • Department of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Advanced Technology Cores, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Texas Children's Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC, 20010, USA; Department of Pediatrics, The George Washington University School of Medicine…

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Yu, Y., Cao, W. M., Cheng, F., Shi, Z., Han, L., Yi, J., da Silva, E. M., Dopeso, H., Chen, H., Yang, J., Wang, X., Zhang, C., & Zhang, H. (2024). FOXK2 amplification promotes breast cancer development and chemoresistance. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217074

Vancouver

Yu Y, Cao WM, Cheng F, Shi Z, Han L, Yi J, et al. FOXK2 amplification promotes breast cancer development and chemoresistance. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217074

BibTeX
@article{Yu2024,
  author = {Yu, Yang and Cao, Wen-Ming and Cheng, Feng and Shi, Zhongcheng and Han, Lili and Yi, Jinling and da Silva, Edaise M and Dopeso, Higinio and Chen, Hui and Yang, Jianhua and Wang, Xiaosong and Zhang, Chunchao and Zhang, Hong},
  title = {FOXK2 amplification promotes breast cancer development and chemoresistance},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217074}
}
Kostenlos starten →